UNRESECTABLE PARAGANGLIOMA
Clinical trials for UNRESECTABLE PARAGANGLIOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE PARAGANGLIOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE PARAGANGLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for rare adrenal cancers
Disease control OngoingThis study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …
Matched conditions: UNRESECTABLE PARAGANGLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Rare cancer hope: immune drug shows promise in phase 2 trial
Disease control OngoingThis study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…
Matched conditions: UNRESECTABLE PARAGANGLIOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC